Agreements (Details 6) (USD $)	3 Months Ended								12 Months Ended				33 Months Ended	0 Months Ended	1 Months Ended	12 Months Ended	33 Months Ended											0 Months Ended	12 Months Ended		33 Months Ended
	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2013 Novartis	Jun. 30, 2013 Novartis	Mar. 29, 2013 Novartis Right-to-test agreement item	Oct. 31, 2010 Novartis Right-to-test agreement item	Jun. 30, 2013 Novartis Development and Commercialization License	Jun. 30, 2013 Novartis Development and Commercialization License	Mar. 29, 2013 Novartis Development and Commercialization License	Oct. 31, 2010 Novartis Development and Commercialization License	Oct. 31, 2010 Novartis Development and Commercialization License Maximum	Jun. 30, 2013 Novartis Development and Commercialization License Development milestones	Mar. 29, 2013 Novartis Development and Commercialization License Development milestones	Oct. 31, 2010 Novartis Development and Commercialization License Development milestones	Mar. 29, 2013 Novartis Development and Commercialization License Regulatory milestones	Oct. 31, 2010 Novartis Development and Commercialization License Regulatory milestones	Mar. 29, 2013 Novartis Development and Commercialization License Sales milestones	Oct. 31, 2010 Novartis Development and Commercialization License Sales milestones	Mar. 29, 2013 Novartis Exclusive development and commercialization license item	Jun. 30, 2013 Novartis Exclusive development and commercialization license item	Mar. 29, 2013 Novartis Non-exclusive development and commercialization license	Jun. 30, 2013 Novartis Future Technological Improvements	Jun. 30, 2013 Novartis Research Services
Collaborative Agreements disclosures
Term of agreement															3 years
Number of extension terms															2
Term of extension of agreement															1 year
Payments received under collaboration agreement													$ 55,200,000	$ 1,000,000	$ 45,000,000		$ 50,400,000														$ 4,100,000	$ 710,000
License exercise fee, per license																			1,000,000
Potential milestone payments receivable																		199,500,000		199,500,000	5,000,000	22,500,000	22,500,000	77,000,000	77,000,000	100,000,000	100,000,000
Number of development and commercialization licenses taken																												1	1
Number of pre-defined and related undisclosed targets														2
Collaborative Arrangement Agreed Upon License Fee on Conversion of Rights																														5,000,000
Payments received under collaboration agreement in connection with amended agreement														3,500,000
Potential milestone payments under second option																		238,000,000				22,500,000		115,500,000		100,000,000
Allocation of fees to deliverables
Estimated utilization period after commercialization												10 years
Discount rate (as a percent)												16.00%
Estimated term of development and commercialization license																25 years
Amount of arrangement consideration included in license and milestone fees	855,000	22,010,000	429,000	933,000	950,000	999,000	6,025,000	1,187,000	24,227,000	9,161,000	6,393,000					11,100,000
Remaining arrangement consideration to be recognized as license revenue																$ 39,300,000	$ 39,300,000